Hepatocellular CarcinomaPhase 3NCT02576509
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
A Phase 3 study testing Nivolumab and Sorafenib in people with Hepatocellular Carcinoma, run by Bristol-Myers Squibb at 138 sites in 22 countries.
Trial summary
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma
- What is being tested?
- Nivolumab and Sorafenib
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 743 participants
- Where
- 138 sitesin 22 countries
- Study dates
- 7 Dec 2015to 7 Feb 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies
- Locoregional therapy for hepatocellular carcinoma (HCC) must be completed at least 4 weeks prior to the baseline scan
- Child-Pugh Class A
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Who cannot join
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior liver transplant
- Active, known, or suspected autoimmune disease
- Other protocol-defined inclusion/exclusion criteria apply
Trial locations and contacts
138 sites in 22 countries.
138 sites in 22 countries
China24 sites
Local Institution - 0139
Beijing, Beijing Municipality, 100050
Local Institution - 0137
Beijing, Beijing Municipality, 100071
Local Institution - 0140
Beijing, Beijing Municipality, 100142
Local Institution - 0141
Beijing, Beijing Municipality, 100142
Local Institution - 0136
Changchun, Jilin, 130012
Local Institution - 0163
Changchun, Jilin, 130021
Local Institution - 0148
Changsha, Hunan, 410013
Local Institution - 0162
Changsha, Hunan, 410013
Local Institution - 0169
Changzhou, Jiangsu, 213003
Local Institution - 0166
Dalian, Liaoning, 116000
Local Institution - 0152
Fuzhou, Fujian, 350025
Local Institution - 0161
Guangzhou, Guangdong, 510060
Local Institution - 0157
Guangzhou, Guangdong, 510080
Local Institution - 0144
Guangzhou, Guangdong, 510515
Local Institution - 0173
Hangzhou, Zhejiang, 310003
Local Institution - 0146
Hangzhou, Zhejiang, 310022
Local Institution - 0142
Harbin, Heilongjiang, 155040
Local Institution - 0164
Hefei, Anhui, 230061
Local Institution - 0135
Nanjing, Jiangsu, 210002
Local Institution - 0158
Nanning, Guangxi, 530021
Local Institution - 0145
Shanghai, Shanghai Municipality, 200032
Local Institution - 0151
Shanghai, Shanghai Municipality, 200032
Local Institution - 0159
Tianjin, Tianjin Municipality, 300060
Local Institution - 0138
Xi'an, Shan3xi, 710038
Japan19 sites
Local Institution - 0100
Chiba, Chiba, 2608670
Local Institution - 0131
Chiyoda-ku, Tokyo, 101-0062
Local Institution - 0101
Hiroshima, 734-8551
Local Institution - 0105
Kanazawa, Ishikawa-ken, 9208641
Local Institution - 0110
Kawasaki-shi, Kanagawa, 2138587
Local Institution - 0107
Kurume-shi, Fukuoka, 8300011
Local Institution - 0111
Kyoto, Kyoto, 6028566
Local Institution - 0103
Matsuyama, Ehime, 7900024
Local Institution - 0114
Mitaka-shi, Tokyo, 181-8611
Local Institution - 0108
Musashino-shi, Tokyo, 180-8610
Local Institution - 0127
Ogaki-shi, Gifu, 5038502
Local Institution - 0106
Osaka-Sayama-Shi, Osaka, 5898511
Local Institution - 0115
Saga, Saga-ken, 8408571
Local Institution - 0102
Sapporo, Hokkaido, 0600033
Local Institution - 0130
Sapporo, Hokkaido, 0608648
Local Institution - 0126
Shinjuku-ku, Tokyo, 1628655
Local Institution - 0113
Suita, Osaka, 5650871
Local Institution - 0112
Yokohama, Kanagawa, 2320024
Local Institution - 0104
Yokohama, Kanagawa, 2418515
United States17 sites
Local Institution - 0066
Birmingham, Alabama, 35294
Local Institution - 0016
Charlotte, North Carolina, 28204
Local Institution - 0061
Chicago, Illinois, 60637
UT Southwestern Medical Center
Dallas, Texas, 75390
Local Institution - 0020
Los Angeles, California, 90095
Local Institution - 0050
Madison, Wisconsin, 53792
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
Local Institution - 0083
New York, New York, 10029
Local Institution - 0093
New York, New York, 10065
Local Institution - 0095
Philadelphia, Pennsylvania, 19104
Local Institution - 0019
Philadelphia, Pennsylvania, 19107
Local Institution - 0017
San Antonio, Texas, 78229
Local Institution - 0015
San Francisco, California, 94115
Local Institution - 0084
San Francisco, California, 94143
Local Institution - 0026
Seattle, Washington, 98101
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, 98109
Scott & White Memorial Hospital And Clinic
Temple, Texas, 76508
Germany9 sites
Local Institution - 0036
Berlin, 13353
Local Institution - 0037
Essen, 45136
Local Institution - 0167
Frankfurt, 60590
Local Institution - 0034
Hamburg, 20246
Local Institution - 0031
Leipzig, 04103
Local Institution - 0035
Mainz, 55131
Local Institution - 0033
Munich, 81366
Local Institution - 0032
Regensburg, 93053
Local Institution - 0030
Tübingen, 72076
France8 sites
Local Institution - 0071
La Tronche, 38700
Local Institution - 0072
Lille, 59037
Local Institution - 0069
Lyon, 69004
Local Institution - 0073
Montpellier, 34295
Local Institution - 0067
Paris, 75651
Local Institution - 0068
Pessac, 33604
Local Institution - 0070
Rennes, 35042
Local Institution - 0074
Toulouse, 31059
South Korea8 sites
Local Institution - 0125
Daegu, 41944
Local Institution - 0116
Goyang-si, 10408
Local Institution - 0118
Jeollanam-do, 58128
Local Institution - 0117
Seoul, Seocho-gu, 06591
Local Institution - 0123
Seoul, 03080
Local Institution - 0119
Seoul, 03722
Local Institution - 0122
Seoul, 05505
Local Institution - 0124
Seoul, 06351
Taiwan7 sites
Local Institution - 0129
Kaohsiung County, 83301
Local Institution - 0133
Taichung, 40447
Local Institution - 0121
Tainan, 704
Local Institution - 0132
Tainan, 736
Local Institution - 0099
Taipei, 10002
Local Institution - 0120
Taipei, 11217
Local Institution - 0128
Taoyuan County, 33305
Australia6 sites
Local Institution - 0007
Adelaide, South Australia, 5000
Local Institution - 0005
Camperdown, New South Wales, 2050
Local Institution - 0001
Clayton, Victoria, 3168
Local Institution - 0002
Heidelberg, Victoria, 3084
Local Institution - 0008
Nedlands, Western Australia, 6009
Local Institution - 0003
Prahran, Victoria, 3181
Italy5 sites
Local Institution - 0054
Benevento, 82100
Local Institution - 0062
Bergamo, 0
Local Institution - 0055
Milan, 20133
Local Institution - 0063
Orbassano, 10043
Local Institution - 0064
Siena, 53100
Israel4 sites
Local Institution - 0082
Haifa, 31096
Local Institution - 0060
Jerusalem, 91120
Local Institution - 0058
Petah Tikva, 49100
Local Institution - 0059
Tel Aviv, 64239
Spain4 sites
Local Institution - 0065
Alicante, 03010
Local Institution - 0085
Majadahonda - Madrid, 28222
Local Institution - 0009
Pamplona, 31008
Local Institution - 0010
Santiago Compostela, 15706
United Kingdom4 sites
Local Institution - 0079
Glasgow, Lanarkshire, G12 0YN
Local Institution - 0081
Liverpool, L7 8YA
Local Institution - 0080
London, Greater London, NW3 2QG
Local Institution - 0078
London, Greater London, SE5 9RS
Belgium3 sites
Local Institution - 0075
Brussels, 1000
Local Institution - 0091
Leuven, 3000
Local Institution - 0077
Liège, 4000
Canada3 sites
Local Institution - 0043
Calgary, Alberta, T2N 4N2
Local Institution - 0042
Québec, Quebec, G1R 2J6
Local Institution - 0044
Vancouver, British Columbia, V5Z 4E6
Czechia3 sites
Local Institution - 0029
Brno, 656 53
Local Institution - 0027
Hradec Králové, 500 05
Local Institution - 0028
Olomouc, 779 00
Poland3 sites
Local Institution - 0023
Gdansk, 80952
Local Institution - 0056
Warsaw, 02-781
Local Institution - 0045
Wroclaw, 50-556
Austria2 sites
Local Institution - 0039
Graz, 8036
Local Institution - 0038
Vienna, 1090
Hong Kong2 sites
Local Institution - 0011
Hong Kong, 0
Local Institution - 0012
Hong Kong
Singapore2 sites
Local Institution - 0013
Singapore, 168583
Local Institution - 0014
Singapore, 308433
Sweden2 sites
Local Institution - 0088
Gothenburg, 413 45
Local Institution - 0087
Stockholm, 141 86
Switzerland2 sites
Local Institution - 0040
Basel, 4031
Local Institution - 0041
Bern, 3010
About this study
Official title: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Conditions
- Hepatocellular Carcinoma
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Nivolumab | Experimental | Nivolumab specified dose on specified days Receives: Drug: Nivolumab |
| Sorafenib | Active comparator | Sorafenib specified dose on specified days Receives: Drug: Sorafenib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause in all randomized participants. Participants who are alive will be censored at the last known alive dates.
Based on Kaplan-Meier Estimates.
Measured: time from the date of randomization to the date of death due to any cause, assessed up to June 2019 (approximately 41 months)
Secondary outcomes (4)
Objective Response Rate (ORR) Per BICR RECIST 1.1
ORR is defined as the proportion of participants whose best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR is defined as the best response designation, as determined based on BICR-assessed tumor response according to RECIST 1.1, recorded between the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For participants without documented progression or subsequent anti-cancer therapy, all available response designations will contribute to the BOR determination. For a BOR of CR or PR, the initial response assessment must be confirmed by a consecutive assessment no less than 4 weeks (28 days) later.
Estimate of (Nivolumab - Sorafenib) is based on CMH method of weighting, stratified by stratification factors
Measured: the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first, assessed up to May 2019 (approximately 40 months)
Progression-Free Survival (PFS)
PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression as assessed by BICR according to RECIST 1.1 or death due to any cause in all randomized participants. Participants who die without a reported prior progression and without initiation of subsequent anti-cancer therapy will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last tumor assessment. Participants who did not have baseline tumor assessment will be censored on the date they were randomized. Participants who did not have any on study tumor assessments and did not die will be censored on the date they were randomized. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last tumor assessment prior to subsequent anti-cancer therapy.
Measured: time from the date of randomization to the date of the first objectively documented tumor progression or death, assessed up to May 2019 (approximately 40 months)
Efficacy Based on PD-L1 Expression - OS and PFS
PD-L1 expression is defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per Dako PD-L1 IHC assay unless otherwise specified. This is referred as quantifiable PD-L1 expression. If the PD-L1 staining could not be quantified, it is further classifies as:
Indeterminate: Tumor cell membrane staining hampered for reasons attributed to the biology of the tumor biopsy specimen and not because of improper sample preparation or handling.
Not evaluable: Tumor biopsy specimen was not optimally collected or prepared (e.g. PD-L1 expression is neither quantifiable nor indeterminate).
PD-L1 status is a dichotomized variable using an X% cut-off for quantifiable PD-L1 expression:
- PD-L1 > X %: ≥ X % PD-L1 expression
- PD-L1 < X %: < X % PD-L1 expression where X% denotes the PD-L1 expression cut-off of 1%. Additional cut off values may also be explored.
Confidence interval based on the Clopper and Pearson method.
Measured: the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first, assessed up to May 2019 (approximately 40 months)
Efficacy Based on PD-L1 Expression - ORR
PD-L1 expression is defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per Dako PD-L1 IHC assay unless otherwise specified. This is referred as quantifiable PD-L1 expression. If the PD-L1 staining could not be quantified, it is further classifies as:
Indeterminate: Tumor cell membrane staining hampered for reasons attributed to the biology of the tumor biopsy specimen and not because of improper sample preparation or handling.
Not evaluable: Tumor biopsy specimen was not optimally collected or prepared (e.g. PD-L1 expression is neither quantifiable nor indeterminate).
PD-L1 status is a dichotomized variable using an X% cut-off for quantifiable PD-L1 expression:
- PD-L1 > X %: ≥ X % PD-L1 expression
- PD-L1 < X %: < X % PD-L1 expression where X% denotes the PD-L1 expression cut-off of 1%. Additional cut off values may also be explored.
Confidence interval based on the Clopper and Pearson method.
Measured: the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first, assessed up to May 2019 (approximately 40 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2015 (estimated)
- Study start7 Dec 2015
- Primary completion30 May 2019
- Study completion7 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 743 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- Responsible party
- Sponsor
- Investigators
- Bristol Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02576509
- Sponsor's protocol ID
- CA209-459
- Status last verified
- Jan 2025
- First submitted
- 13 Oct 2015
- Last updated
- 17 Feb 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz A, Kelley RK. Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial. JHEP Rep. 2026 Sep 19:102038. doi: 10.1016/j.jhepr.2026.102038. Online ahead of print.
PubMed 42762856Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi: 10.1148/radiol.232875.
PubMed 39560477Zhou X, Cao J, Topatana W, Xie T, Chen T, Hu J, Li S, Juengpanic S, Lu Z, Zhang B, Wang K, Feng X, Shen J, Chen M. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy. 2023 Apr;15(5):353-365. doi: 10.2217/imt-2022-0168. Epub 2023 Feb 27.
PubMed 36852452Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer. 2022 Nov 15;128(22):3995-4003. doi: 10.1002/cncr.34457. Epub 2022 Sep 16.
PubMed 36111952Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer. 2022 Jan;10(1):e003133. doi: 10.1136/jitc-2021-003133.
PubMed 35101942Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
PubMed 34914889
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
- ClinicalTrials.gov ID
- NCT02576509
- Acronym / sponsor ID
- CA209-459
- Conditions
- Hepatocellular Carcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 743 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- Study start
- 7 Dec 2015 (actual)
- Primary completion
- 30 May 2019 (actual)
- Study completion
- 7 Feb 2024 (actual)
- First posted
- 15 Oct 2015 (estimated)
- Results
- Posted 26 Jun 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nivolumab | Experimental | Drug: NivolumabNivolumab specified dose on specified days |
| Sorafenib | Active comparator | Drug: SorafenibSorafenib specified dose on specified days |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies
- Locoregional therapy for hepatocellular carcinoma (HCC) must be completed at least 4 weeks prior to the baseline scan
- Child-Pugh Class A
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Key exclusion criteria (4 listed)
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior liver transplant
- Active, known, or suspected autoimmune disease
- Other protocol-defined inclusion/exclusion criteria apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NivolumabSpecified Dose on Specified Days | Drug | Nivolumab |
| SorafenibSpecified Dose on Specified Days | Drug | Sorafenib |
Primary outcome
Overall Survival (OS)
Time frame: time from the date of randomization to the date of death due to any cause, assessed up to June 2019 (approximately 41 months)
OS is defined as the time from the date of randomization to the date of death due to any cause in all randomized participants. Participants who are alive will be censored at the last known alive dates. Based on Kaplan-Meier Estimates.
4 secondary outcomes
Objective Response Rate (ORR) Per BICR RECIST 1.1
Time frame: the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first, assessed up to May 2019 (approximately 40 months)
Progression-Free Survival (PFS)
Time frame: time from the date of randomization to the date of the first objectively documented tumor progression or death, assessed up to May 2019 (approximately 40 months)
Efficacy Based on PD-L1 Expression - OS and PFS
Time frame: the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first, assessed up to May 2019 (approximately 40 months)
Efficacy Based on PD-L1 Expression - ORR
Time frame: the date of randomization and the date of first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first, assessed up to May 2019 (approximately 40 months)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42762856Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz A, Kelley RK. Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial. JHEP Rep. 2026 Sep 19:102038. doi: 10.1016/j.jhepr.2026.102038. Online ahead of print.
- Derived from this study: PubMed 39560477Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi: 10.1148/radiol.232875.
- Derived from this study: PubMed 36852452Zhou X, Cao J, Topatana W, Xie T, Chen T, Hu J, Li S, Juengpanic S, Lu Z, Zhang B, Wang K, Feng X, Shen J, Chen M. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy. 2023 Apr;15(5):353-365. doi: 10.2217/imt-2022-0168. Epub 2023 Feb 27.
- Derived from this study: PubMed 36111952Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer. 2022 Nov 15;128(22):3995-4003. doi: 10.1002/cncr.34457. Epub 2022 Sep 16.
- Derived from this study: PubMed 35101942Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer. 2022 Jan;10(1):e003133. doi: 10.1136/jitc-2021-003133.
- Derived from this study: PubMed 34914889Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
- BMS Clinical Trial InformationLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Related trials for Hepatocellular Carcinoma
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol Myers Squibb study director
Bristol-Myers Squibb
138 sites in 22 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Nivolumab and Sorafenib in people with Hepatocellular Carcinoma, run by Bristol-Myers Squibb at 138 sites in 22 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 138 sites in China, Japan, United States, Germany, France and 17 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Jun 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: time from the date of randomization to the date of death due to any cause, assessed up to June 2019 (approximately 41 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02576509, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2025.